Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


  • Investor group comprising Camac Partners LLCConcord Investment Partners Ltd, and Leonite Capital LLC condemned Pasithea Therapeutics Corp's (NASDAQ: KTTA) recently announced the acquisition of AlloMek Therapeutics LLC.
  • The investors, collectively the largest stockholder of the company, said, "We are disgusted that less than two weeks after acknowledging stockholders' request to call a Special Meeting intended to decide the fate of the current Board, Pasithea's incumbent directors decided to proceed with a second highly dilutive acquisition within the last six months." 
  • "In our view, the company's stockholders should consider this a clear sign that investor feedback is being dismissed and urgent change is needed in the boardroom," they added.
  • Related: EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition.
  • The investors said that at the company's last annual meeting, fewer than 6 million shares were voted "For" each of the incumbent directors. While the investors received support suggesting clear evidence of investor dissatisfaction with the Board.
  • In June, Pasithea acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody for amyotrophic lateral sclerosis and other neuroinflammatory disorders, for $3.75 million.
  • Price Action: KTTA shares traded 0.79% lower at $1.24 on the last check Friday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechM&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs